Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 7:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 181 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coronary Thrombosis Clear all
Completed No phase listed Observational Results available

XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA-Phase 1)

NCT00676520
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
XIENCE V® Everolimus Eluting Coronary Stent
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
8,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2012 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Not applicable Interventional

Prospective Randomized On-X Versus SJM Evaluation Trial

NCT00639782
View directory record Official record
Conditions
Heart Valve Disease
Interventions
On-X Heart valve replacement, SJM Heart valve replacement
Device
Lead sponsor
On-X Life Technologies, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Honolulu, Hawaii • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Not applicable Interventional Results available

Resolute Integrity US Extended Length Sub-Study(RI US XL)

NCT01913600
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity Stent
Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 4 Interventional Results available

Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)

NCT02486367
View directory record Official record
Conditions
Aortic Stenosis, Inflammation, Thrombosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Sep 24, 2026, 7:56 PM EDT
Withdrawn Phase 2 Interventional

Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli

NCT02378623
View directory record Official record
Conditions
Patent Foramen Ovale, Cardiac Implantable Electronic Device
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 24, 2026, 7:56 PM EDT
Recruiting Phase 4 Interventional

Aspirin and Hemocompatibility Events in Chronic Advanced Heart Failure Patients With Assist Device

NCT06655376
View directory record Official record
Conditions
Bleeding, Clot Blood
Interventions
Aspirin, Warfarin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 24, 2026, 7:56 PM EDT
Completed No phase listed Observational

Risk of Developing Antibodies to Heparin-PF4 After Heart Surgery

NCT00237328
View directory record Official record
Conditions
Thrombosis
Interventions
Heparin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Rochester, Minnesota • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2013 · Synced Sep 24, 2026, 7:56 PM EDT
Completed No phase listed Observational

Pre-surgical Evaluation for the Quantra System in Adult Patients Undergoing Cardiac Surgery

NCT03931031
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Sep 24, 2026, 7:56 PM EDT
Withdrawn No phase listed Observational

Pulse Wave Analysis in Advanced Heart Failure

NCT01642927
View directory record Official record
Conditions
Left Ventricular Assist Device, Heart Failure, Intra-aortic Balloon Pump, LVAD Clot, LVAD-related GI Bleed
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).

NCT03539055
View directory record Official record
Conditions
Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis, Watchman LAA Closure Device
Interventions
Dabigatran Etexilate Oral Capsule
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Not applicable Interventional Results available

Heparin and the Reduction of Thrombosis (HART) Trial

NCT00779558
View directory record Official record
Conditions
Thrombosis
Interventions
Heparin sulfate infusion at 10 units/kg/hour, Placebo infusion
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Day to 1 Year
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2011 · Synced Sep 24, 2026, 7:56 PM EDT
Completed No phase listed Observational

Platelet Sub-study of the TWILIGHT Trial

NCT04001374
View directory record Official record
Conditions
Coronary Artery Disease, Myocardial Infarction
Interventions
Ticagrelor, ASA
Drug
Lead sponsor
Juan Badimon
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 24, 2026, 7:56 PM EDT
Completed No phase listed Observational

EXCEL Clinical Trial (Universal Registry)

NCT01205789
View directory record Official record
Conditions
Chronic Coronary Occlusion, Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions
Not listed
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Santa Clara, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Not applicable Interventional

PREVENtion of HeartMate II Pump Thrombosis

NCT02158403
View directory record Official record
Conditions
HeartMate II Pump Thrombosis
Interventions
Clinical Management Recommendations for reducing pump thrombosis
Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 3 Interventional Results available

Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

NCT00781391
View directory record Official record
Conditions
Stroke, Atrial Fibrillation, Embolism
Interventions
warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
21 Years and older
Enrollment
21,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
316
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing Off-Pump Coronary Artery Bypass Grafting (CABG) (CHOOSE)

NCT00073580
View directory record Official record
Conditions
Thrombocytopenia, Thrombosis, Cardiac Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 4 Interventional Results available

Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis

NCT02053909
View directory record Official record
Conditions
Saphenous Vein Graft Disease
Interventions
Aspirin, Ticagrelor
Drug
Lead sponsor
Boca Raton Regional Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 24, 2026, 7:56 PM EDT
Completed No phase listed Observational

A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

NCT02345356
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Cardiac Valvular Insufficiency, Coagulopathies, Pulmonary Embolism
Interventions
Genotype-guided, Standard-of-Care
Genetic · Other
Lead sponsor
University of Puerto Rico
Other
Eligibility
21 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 24, 2026, 7:56 PM EDT
Terminated Phase 3 Interventional

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

NCT00557921
View directory record Official record
Conditions
Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions
CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
247
States / cities
Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Not applicable Interventional Results available

Randomized Trial of Interventions to Improve Warfarin Adherence

NCT00904982
View directory record Official record
Conditions
Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies
Interventions
Financial Incentive and Med-eMonitor, 2Med-eMonitor
Behavioral · Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Phase 4 Interventional Results available

Clopidogrel Monotherapy in Patients With High Bleeding Risk

NCT05223335
View directory record Official record
Conditions
Bleeding Complications
Interventions
Clopidogrel, Prasugrel, Tricagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Sep 24, 2026, 7:56 PM EDT
Recruiting Not applicable Interventional

Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics

NCT06523166
View directory record Official record
Conditions
Device Related Thrombosis, Peri-device Leak
Interventions
Transesophageal echocardiography (TEE), Cardiac CTA
Procedure
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Los Angeles, California • Roslyn, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 24, 2026, 7:56 PM EDT
Completed Not applicable Interventional Results available

Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information

NCT00401414
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation
Interventions
Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Sep 24, 2026, 7:56 PM EDT